Disposition of eslicarbazepine acetate in the mouse after oral administration

Fundamental and Clinical Pharmacology

Volumn 22, Issue 5, 2008, Pages 529-536

  Alves, Gilberto ^a   Figueiredo, Isabel ^a   Castel Branco, Margarida ^a   Lourenço, Nulita ^b   Falcão, Amílcar ^a   Caramona, Margarida ^a   Soares Da Silva, Patrício ^c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Hospital Amato Lusitano   (Portugal)

^c DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

Eslicarbazepine acetate; Metabolism; Mouse; Oxcarbazepine; Tissue disposition

Indexed keywords

ANTICONVULSIVE AGENT; DRUG METABOLITE; ESLICARBAZEPINE ACETATE; LICARBAZEPINE; OXCARBAZEPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DIFFUSION; DRUG DISPOSITION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SINGLE DRUG DOSE; SPECIES DIFFERENCE;

ADMINISTRATION, ORAL; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DIBENZAZEPINES; LIVER; MALE; METABOLIC CLEARANCE RATE; MICE; TISSUE DISTRIBUTION;

EID: 52649131374     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00617.x     Document Type: Article

References (34)

1. Brodie M.J., Kwan P. Epilepsy in elderly people. BMJ (2005) 331 1317 1322.
2. Mac T.L., Tran D.S., Quet F., Odermatt P., Preux P.M., Tan T.C. Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review. Lancet Neurol. (2007) 6 533 543.
3. Mcewan M.J., Espie C.A., Metcalfe J. A systematic review of the contribution of qualitative research to the study of quality of life in children and adolescents with epilepsy. Seizure (2004) 13 3 14.
4. Guekht A.B., Mitrokhina T.V., Lebedeva A.V. et al. Factors influencing on quality of life in people with epilepsy. Seizure (2007) 16 128 133.
5. Kwan P., Brodie M. Refractory epilepsy: a progressive, intractable but preventable condition? Seizure (2002) 11 77 84.
6. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin. Investig. Drugs (2006) 15 637 647.
7. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Perucca E., Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. (2007) 73 1 52.
8. Almeida L., Soares-da-Silva P. Eslicarbazepine Acetate (BIA 2-093). Neurotherapeutics (2007) 4 88 96.
9. Benes J., Parada A., Figueiredo A.A. et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5- carboxamide derivatives. J. Med. Chem. (1999) 42 2582 2587.
10. Schachter S.C. Oxcarbazepine: current status and clinical applications. Expert Opin. Investig. Drugs (1999) 8 1103 1112.
11. Almeida L., Soares-da-Silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J. Clin. Pharmacol. (2004) 44 906 918.
12. Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clin. Drug Investig. (2004) 24 185 203.
13. Flesch G., Francotte E., Hell F., Degen P.H. Determination of the R-(-) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography. J. Chromatogr. (1992) 581 147 151.
14. Volosov A., Xiaodong S., Perucca E., Yagen B., Sintov A., Bialer M. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin. Pharmacol. Ther. (1999) 66 547 553.
15. May T.W., Korn-Merker E., Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin. Pharmacokinet. (2003) 42 1023 1042.
16. Almeida L., Soares-da-Silva P. Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs R D (2003) 4 269 284.
17. Almeida L., Falcão A., Maia J., Mazur D., Gellert M., Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J. Clin. Pharmacol. (2005) 45 1062 1066.
18. McLean M.J., Schmutz M., Wamil A.W., Olpe H.R., Portet C., Feldmann K.F. Oxcarbazepine: mechanisms of action. Epilepsia (1994) 35 S5 S9.
19. Schmutz M., Brugger F., Gentsch C., McLean M.J., Olpe H.R. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia (1994) 35 S47 S50.
20. Bialer M. Oxcarbazepine: chemistry, biotransformation, and pharmacokinetics, in : Levy R.H., Mattson R., Meldrum B.S., Perucca E. (Eds Antiepileptic Drugs, Lippincott-Williams & Wilkins, Philadelphia, PA, 2002, pp. 459 465.
21. Misl'anová C., Hutta M. Role of biological matrices during the analysis of chiral drugs by liquid chromatography. J. Chromatogr. B (2003) 797 91 109.
22. Hainzl D., Parada A., Soares-da-Silva P. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res. (2001) 44 197 206.
23. Alves G., Figueiredo I., Castel-Branco M., Loureiro A., Falcão A., Caramona M. Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R-licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection. Anal. Chim. Acta (2007) 596 132 140.
24. Elger C., Bialer M., Cramer J.A., Maia J., Almeida L., Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia (2007) 48 497 504.
25. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Perucca E., Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. (2004) 61 1 48.
26. Maia J., Vaz-da-Silva M., Almeida L. et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D (2005) 6 201 206.
27. González-Esquivel D.F., Ortega-Gavilán M., Alcántara-López G., Jung-Cook H. Plasma level monitoring of oxcarbazepine in epileptic patients. Arch. Med. Res. (2000) 31 202 205.
28. Arellano C., Philibert C., Vachoux C., Woodley J., Houin G. Validation of a liquid chromatography-mass spectrometry method to assess the metabolism of bupropion in rat everted gut sacs. J. Chromatogr. B (2005) 829 50 55.
29. Arellano C., Philibert C., Dane à Yakan E.N. et al. Validation of a liquid chromatography-mass spectrometry method to assess the metabolism of dextromethorphan in rat everted gut sacs. J. Chromatogr. B (2005) 819 102 113.
30. Arellano C., Philibert C., Vachoux C., Woodley J., Houin G. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs. J. Pharm. Pharm. Sci. (2007) 10 26 36.
31. Clinckers R., Smolders I., Meurs A., Ebinger G., Michotte Y. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxacarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J. Pharmacol. Exp. Ther. (2005) 314 725 731.
32. Marchi N., Guiso G., Rizzi M. et al. A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia (2005) 46 1613 1620.
33. Tong X., Patsalos P.N. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br. J. Pharmacol. (2001) 133 867 874.
34. Shen J., Fraga C., Calabrese C., McCarville M.B., Schaiquevich P., Stewart C.F. A modified surgical procedure for microdialysis probe implantation in the lateral ventricle of a FVB mouse. J. Pharm. Sci. (2008) in press.